vs

Side-by-side financial comparison of BioAge Labs, Inc. (BIOA) and DATA I/O CORP (DAIO). Click either name above to swap in a different company.

DATA I/O CORP is the larger business by last-quarter revenue ($4.0M vs $3.1M, roughly 1.3× BioAge Labs, Inc.). DATA I/O CORP runs the higher net margin — -69.0% vs -842.9%, a 773.8% gap on every dollar of revenue. DATA I/O CORP produced more free cash flow last quarter ($-1.9M vs $-28.4M).

Altos Labs, Inc. is an American biotechnology research company. Altos Labs' goal is to develop life extension therapies that can halt or reverse the human aging process. Specialized cell therapies based on induced pluripotent stem cells are to be developed for this purpose. Russian-born technology businessman Yuri Milner, along with investors including Jeff Bezos, funded the company in 2021, operations started in 2022.

Data I/O Corporation is a provider of manual and automated data programming and security provisioning systems for flash memory, microcontrollers, and logic devices. Founded in 1969 and incorporated in 1972, the company developed equipment that allowed electronic designers to program non-volatile semiconductor devices with data stored on punched cards or ASCII-encoded (eight-level) punched paper tape. These products were used for the design and manufacturing of systems used in industries such ...

BIOA vs DAIO — Head-to-Head

Bigger by revenue
DAIO
DAIO
1.3× larger
DAIO
$4.0M
$3.1M
BIOA
Higher net margin
DAIO
DAIO
773.8% more per $
DAIO
-69.0%
-842.9%
BIOA
More free cash flow
DAIO
DAIO
$26.5M more FCF
DAIO
$-1.9M
$-28.4M
BIOA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BIOA
BIOA
DAIO
DAIO
Revenue
$3.1M
$4.0M
Net Profit
$-25.9M
$-2.8M
Gross Margin
43.0%
Operating Margin
-923.4%
-62.8%
Net Margin
-842.9%
-69.0%
Revenue YoY
-23.2%
Net Profit YoY
-132.7%
EPS (diluted)
$-0.72
$-0.29

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOA
BIOA
DAIO
DAIO
Q4 25
$3.1M
$4.0M
Q3 25
$2.1M
$5.4M
Q2 25
$2.4M
$5.9M
Q1 25
$1.5M
$6.2M
Q4 24
$5.2M
Q3 24
$0
$5.4M
Q2 24
$5.1M
Q1 24
$6.1M
Net Profit
BIOA
BIOA
DAIO
DAIO
Q4 25
$-25.9M
$-2.8M
Q3 25
$-20.2M
$-1.4M
Q2 25
$-21.6M
$-742.0K
Q1 25
$-12.9M
$-382.0K
Q4 24
$-1.2M
Q3 24
$-23.4M
$-307.0K
Q2 24
$-797.0K
Q1 24
$-807.0K
Gross Margin
BIOA
BIOA
DAIO
DAIO
Q4 25
43.0%
Q3 25
50.7%
Q2 25
49.8%
Q1 25
51.6%
Q4 24
52.2%
Q3 24
53.9%
Q2 24
54.5%
Q1 24
52.8%
Operating Margin
BIOA
BIOA
DAIO
DAIO
Q4 25
-923.4%
-62.8%
Q3 25
-1126.6%
-25.8%
Q2 25
-1027.0%
-14.2%
Q1 25
-1133.4%
-6.1%
Q4 24
-24.8%
Q3 24
-6.0%
Q2 24
-11.2%
Q1 24
-14.1%
Net Margin
BIOA
BIOA
DAIO
DAIO
Q4 25
-842.9%
-69.0%
Q3 25
-982.0%
-25.3%
Q2 25
-894.0%
-12.5%
Q1 25
-891.0%
-6.2%
Q4 24
-22.8%
Q3 24
-5.7%
Q2 24
-15.7%
Q1 24
-13.2%
EPS (diluted)
BIOA
BIOA
DAIO
DAIO
Q4 25
$-0.72
$-0.29
Q3 25
$-0.56
$-0.15
Q2 25
$-0.60
$-0.08
Q1 25
$-0.36
$-0.04
Q4 24
$-0.13
Q3 24
$-6.70
$-0.03
Q2 24
$-0.09
Q1 24
$-0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOA
BIOA
DAIO
DAIO
Cash + ST InvestmentsLiquidity on hand
$281.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$272.1M
$13.5M
Total Assets
$294.9M
$20.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOA
BIOA
DAIO
DAIO
Q4 25
$281.1M
Q3 25
$285.8M
Q2 25
$297.3M
Q1 25
$320.5M
Q4 24
Q3 24
$334.5M
Q2 24
Q1 24
Total Debt
BIOA
BIOA
DAIO
DAIO
Q4 25
Q3 25
Q2 25
Q1 25
$7.1M
Q4 24
Q3 24
$9.9M
Q2 24
Q1 24
Stockholders' Equity
BIOA
BIOA
DAIO
DAIO
Q4 25
$272.1M
$13.5M
Q3 25
$277.5M
$16.0M
Q2 25
$294.8M
$17.2M
Q1 25
$313.2M
$17.5M
Q4 24
$17.6M
Q3 24
$313.7M
$19.2M
Q2 24
$18.9M
Q1 24
$19.6M
Total Assets
BIOA
BIOA
DAIO
DAIO
Q4 25
$294.9M
$20.2M
Q3 25
$305.1M
$22.7M
Q2 25
$322.1M
$24.1M
Q1 25
$343.8M
$24.5M
Q4 24
$25.0M
Q3 24
$337.4M
$24.8M
Q2 24
$24.1M
Q1 24
$26.2M
Debt / Equity
BIOA
BIOA
DAIO
DAIO
Q4 25
Q3 25
Q2 25
Q1 25
0.02×
Q4 24
Q3 24
0.03×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOA
BIOA
DAIO
DAIO
Operating Cash FlowLast quarter
$-28.3M
$-1.7M
Free Cash FlowOCF − Capex
$-28.4M
$-1.9M
FCF MarginFCF / Revenue
-921.5%
-46.6%
Capex IntensityCapex / Revenue
3.6%
5.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-82.3M
$-2.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOA
BIOA
DAIO
DAIO
Q4 25
$-28.3M
$-1.7M
Q3 25
$-16.0M
$-343.0K
Q2 25
$-20.0M
$-342.0K
Q1 25
$-17.4M
$109.0K
Q4 24
$-1.6M
Q3 24
$839.0K
Q2 24
$-243.0K
Q1 24
$-41.0K
Free Cash Flow
BIOA
BIOA
DAIO
DAIO
Q4 25
$-28.4M
$-1.9M
Q3 25
$-16.1M
$-348.0K
Q2 25
$-20.1M
$-633.0K
Q1 25
$-17.8M
$53.0K
Q4 24
$-1.7M
Q3 24
$724.0K
Q2 24
$-268.0K
Q1 24
$-180.0K
FCF Margin
BIOA
BIOA
DAIO
DAIO
Q4 25
-921.5%
-46.6%
Q3 25
-782.2%
-6.5%
Q2 25
-834.5%
-10.6%
Q1 25
-1226.0%
0.9%
Q4 24
-33.5%
Q3 24
13.4%
Q2 24
-5.3%
Q1 24
-3.0%
Capex Intensity
BIOA
BIOA
DAIO
DAIO
Q4 25
3.6%
5.2%
Q3 25
1.1%
0.1%
Q2 25
6.6%
4.9%
Q1 25
29.4%
0.9%
Q4 24
3.6%
Q3 24
2.1%
Q2 24
0.5%
Q1 24
2.3%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BIOA
BIOA

Segment breakdown not available.

DAIO
DAIO

Other$2.1M53%
Adapter Sales$1.9M47%

Related Comparisons